Patients with PSA below 0.2 ng/mL at 8 years post high‐dose‐rate brachytherapy have an extremely low risk of subsequent recurrence

Abstract

ObjectivesWe have analyzed the long‐term follow‐up data of patients with prostate cancer (PCa) who underwent high‐dose‐rate brachytherapy (HDR–BT) and external beam radiotherapy (EBRT) combined with long‐term androgen deprivation therapy (ADT). The objective was to determine the optimal time for cessation of PSA monitoring after HDR–BT.MethodsWe included 309 patients with clinical stage T1c‐T4 N0–1 M0 PCa who received HDR‐BT and EBRT combined with long‐term ADT between 2005 and 2018. We stratified the patients based on their prostate‐specific antigen (PSA) levels and identified the factors associated with biochemical recurrence (BCR) and clinical progression (CP).ResultsThe median follow‐up duration was 98 months (range: 31–207 months). Among the 306 patients, 76 developed BCR and 47 developed CP subsequently. We found that the PSA levels at 3, 5, and 8 years significantly correlated with the oncological outcomes of brachytherapy. No patient with a PSA level ≤ 0.2 ng/mL at 8 years later developed BCR or CP.ConclusionOur long‐term data suggest that in the presence of a PSA level ≤ 0.2 ng/mL at 8 years later, PSA monitoring may be safely discontinued due to the extremely low risk of subsequent oncological events. The data presented in this study will assist clinicians in determining the optimal management strategy for patients with PCa following HDR–BT and EBRT combined with long‐term ADT.